Skip to content

Study · Randomized controlled trial · n = 22 · 2019

15 results

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.

Nagaike H, Ohara M, Kohata Y, Hiromura M, Tomoyasu M, Takada M, Yamamoto T, Hayashi T, Fukui T, Hirano T

Diabetes therapy : research, treatment and education of diabetes and related disorders5 Jan 2019Cited by 22 (Europe PMC)

PMID30612316 (opens in a new tab)PMCIDPMC6349295 (opens in a new tab)DOI10.1007/s13300-018-0560-8 (opens in a new tab)PepBankPUB-30612316
Read at sourcePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, d-ROMs changes did not differ significantly between dulaglutide and liraglutide.

    In plain wordsIn patients with T2DM, the oxidative stress marker changed similarly with dulaglutide and liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changed-ROMs change
    Study

    n = 22

    Comparator
    Liraglutide
    Analysis
    Primary
    Outcome group
    Oxidative stress · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment.
    2 context sentences
    Summary · context
    The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI).
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, d-ROMs changes did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn patients with T2DM, the oxidative stress marker changed similarly with liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changed-ROMs change
    Study

    n = 22

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Oxidative stress · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment.
    2 context sentences
    Summary · context
    The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI).
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, L-RHI changes did not differ significantly between dulaglutide and liraglutide.

    In plain wordsIn patients with T2DM, the blood vessel function measure changed similarly with dulaglutide and liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeL-RHI change
    Study

    n = 22

    Comparator
    Liraglutide
    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment.
    2 context sentences
    Summary · context
    The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI).
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, L-RHI changes did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn patients with T2DM, the blood vessel function measure changed similarly with liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeL-RHI change
    Study

    n = 22

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment.
    2 context sentences
    Summary · context
    The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI).
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, dulaglutide maintained mean glucose while liraglutide worsened it, favoring dulaglutide.

    In plain wordsIn patients with T2DM, mean blood sugar stayed stable with dulaglutide but worsened with liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMean glucose
    Study

    n = 22

    Comparator
    Liraglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment.
    2 context sentences
    Summary · context
    However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating.
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, liraglutide worsened mean glucose while dulaglutide maintained it.

    In plain wordsIn patients with T2DM, mean blood sugar worsened with liraglutide but stayed stable with dulaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseMean glucose
    Study

    n = 22

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment.
    2 context sentences
    Summary · context
    However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating.
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, dulaglutide maintained glycemic excursion amplitude while liraglutide worsened it, favoring dulaglutide.

    In plain wordsIn patients with T2DM, blood sugar fluctuations stayed stable with dulaglutide but worsened with liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMean amplitude of glycemic excursions
    Study

    n = 22

    Comparator
    Liraglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment.
    2 context sentences
    Summary · context
    However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating.
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, liraglutide worsened glycemic excursion amplitude while dulaglutide maintained it.

    In plain wordsIn patients with T2DM, blood sugar fluctuations worsened with liraglutide but stayed stable with dulaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseMean amplitude of glycemic excursions
    Study

    n = 22

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment.
    2 context sentences
    Summary · context
    However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating.
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, body weight changes did not differ significantly between dulaglutide and liraglutide.

    In plain wordsIn patients with T2DM, weight changes were similar with dulaglutide and liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeBody weight change
    Study

    n = 22

    Comparator
    Liraglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, body weight changes did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn patients with T2DM, weight changes were similar with liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight change
    Study

    n = 22

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, fasting plasma glucose changes did not differ significantly between dulaglutide and liraglutide.

    In plain wordsIn patients with T2DM, fasting blood sugar changes were similar with dulaglutide and liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeFasting plasma glucose change
    Study

    n = 22

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, fasting plasma glucose changes did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn patients with T2DM, fasting blood sugar changes were similar with liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma glucose change
    Study

    n = 22

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, HbA1c changes did not differ significantly between dulaglutide and liraglutide.

    In plain wordsIn patients with T2DM, HbA1c changes were similar with dulaglutide and liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change
    Study

    n = 22

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, HbA1c changes did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn patients with T2DM, HbA1c changes were similar with liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change
    Study

    n = 22

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In patients with T2DM, the DTSQ convenience score improved in the dulaglutide group.

    In plain wordsIn patients with T2DM, treatment convenience improved from baseline in the dulaglutide group.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseDTSQ convenience score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Whole body

    Source sentences

    Summary
    The DTSQ score for "convenience" improved in the dulaglutide group.
    1 context sentence
    Summary · context
    Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.